FibroGen
Claudia Witschi has extensive work experience in the biotechnology and pharmaceutical industry. Claudia began their career as a Ph.D. student at Universite de Geneve in 1993 and continued until 1997. Claudia then joined Genentech as a Postdoc in 1997, where they worked until 1998. In 1999, Claudia joined FibroGen, Inc. as a Senior Director of Formulation Development. Currently, they hold the position of Executive Director of Biologics Drug Product at FibroGen, Inc. starting from July 2022.
Claudia Witschi obtained their Ph.D. in Pharmaceutical Sciences from the University of Geneva, where they studied from 1993 to 1997. Claudia also pursued a Master's degree in Pharmaceutical Sciences at ETH Zürich. However, specific start and end years for this program were not provided. Additionally, Claudia Witschi has attended CCL, but no degree or field of study details are available for this institution.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.